Orforglipron news

All news on Orforglipron (also known as 1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5Hpyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]- and orforglipron): plants, production capacities, investments and involved companies.

4 February 2026

Lilly Q4 2025 Financial Results and 2026 Outlook

Q4 revenue rose 43% to $19.3B, EPS up 51%. FDA approved Kwikpen, expanded Jaypirca use. 2026 revenue guidance: $80B-$83B, EPS: $33.50-$35.00.
18 December 2025

Lilly's Orforglipron Maintains Weight Loss in Phase 3 Trial

Orforglipron met primary and key secondary endpoints for weight maintenance at 52 weeks post-weight loss on Wegovy. FDA submission for obesity treatment is underway.
9 December 2025

Lilly to Invest $6 Billion in Alabama API Facility

The new facility in Huntsville will create 3,450 jobs, focus on small molecule and peptide medicines, and enhance supply chain resilience with advanced technologies. Completion expected by 2032.
3 November 2025

Lilly to Invest $3 Billion in New Netherlands Facility for Oral Medicine Production

The facility in the Netherlands will enhance oral medicine production, create 500 jobs, and support global supply chain with advanced manufacturing technologies.
29 October 2025

Lilly Invests $1.2 Billion in Puerto Rico for U.S. Oral Medicine Manufacturing Expansion

The investment will create 100 manufacturing and 1,000 construction jobs, enhancing production of oral solid medicines with advanced technologies. Construction starts in 2026, production by 2028.

Who will be producing Orforglipron in the future?

Find out with chemXplore Analytics

Learn more